Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG006 in advanced small cell lung cancer or neuroendocrine carcinoma
CTR20241955Phase 2Active
- Sponsor
- Zelgen
- Start
- Aug 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alveltamig in neuroendocrine carcinoma (NEC), small cell lung cancer (SCLC), sponsored by Zelgen. Started Aug 2024; status: active.
02
Drugs
alveltamig
03
Conditions
neuroendocrine carcinoma (NEC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20241955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241955.